drugset / Trial / NCT02256748

Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers

NCT02256748

Phase 1 Completed 20 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The objective of the study was to investigate the effect of BIRT 2584 XX and its metabolite BI 610100 when BIRT 2584 XX is administered as a tablet to near steady state in estimated high therapeutic dose on the pharmacokinetics (PK) of midazolam, a probe substrate for CYP3A4. The PK of midazolam was measured before dosing of BIRT 2584 XX, after a single dose of BIRT 2584 XX and after repeated doses of BIRT 2584 XX for 3 and 12 days

Timeline

Start
2005-06
Primary completion
2005-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BIRT 2584 XX Unknown 500 mg Oral
Subject Midazolam Small molecule

Indications

No indication recorded.